Jci_page_head_homepage_01 Jci_page_head_homepage_02
Leander Grode, Peter Seiler, Sven Baumann, Jürgen Hess, Volker Brinkmann, Ali Nasser Eddine, Peggy Mann, Christian Goosmann, Silke Bandermann, Debbie Smith, Gregory J. Bancroft, Jean-Marc Reyrat, Dick van Soolingen, Bärbel Raupach, Stefan H.E. Kaufmann
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2472–2479 doi:10.1172/JCI24617
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

High safety profile of hly+ rBCG and ΔureC hly+ rBCG vaccines. (A) SCID immune-deficient mutant mice were vaccinated i.v. with 0.5 – 1 × 108 CFU of hly+ rBCG (diamonds), ΔureC hly+ rBCG (triangles), and parental BCG (squares) to determine survival rate. P = 0.001 for hly+ rBCG compared with parental BCG, and P < 0.001 for ΔureC hly+ rBCG compared with parental BCG. (B) RAG1–/– immunodeficient mutant mice were vaccinated i.v. with 0.5 – 1 × 106 CFU of hly+ rBCG (diamonds), ΔureC hly+ rBCG (triangles), and parental BCG (squares) to determine bacterial load in lung and spleen. Differences were not statistically significant (P = 0.7 for lung and P = 0.5 for spleen; Mann-Whitney U test). Shown is 1 representative experiment of each of 2 similar experiments.